clinical trial · NCT00199381
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
Kyowa Kirin, Inc.·phase3·terminated·n = 504
Parkinson's DiseaseIstradefylline
brief summary
This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
started
Oct 1, 2005
primary completion
Oct 1, 2008
completion
Oct 1, 2008
last updated
May 17, 2024
detailed description
Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind study 6002-INT-001 are eligible to enter into this long-term open safety study with a starting istradefylline dose of 20 or 40mg per day.
official title
An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol